Effects of fermented milk containing Lacticaseibacillus paracasei strain Shirota on constipation and gut microbiota: A randomised pilot study in Vietnam

Fermented milk containing Lacticaseibacillus paracasei strain Shirota (LcS) has been shown to improve stool consistency in various countries; however, its effect on hard or lumpy stools (HLS) in the Vietnamese population remains unclear. We investigated the effects of LcS-fermented milk on constipated Vietnamese adults with a high prevalence of HLS. In a single-centre, open-label trial, 51 participants with HLS were randomised to receive one bottle per day of fermented milk containing ≥6.5 × 109 cfu of LcS for 4 weeks (probiotic group) or no intervention (control group), followed by a 2-week washout. The primary endpoint was the proportion of participants with HLS (Bristol Stool Form Scale score of 1 or 2) in ≥25% of bowel movements over 4 weeks. Secondary endpoints included total stool frequency, HLS frequency, ideal stool form, and defecation-related symptoms - all recorded in daily diaries. The Chinese Constipation Questionnaire (CCQ) and gut microbiota composition (16S rRNA sequencing) were assessed every 2 weeks. During the intervention, the probiotic group had a significantly lower proportion of participants with HLS in ≥25% of bowel movements compared to controls (odds ratio: 0.00; 95% confidence interval: 0.00-0.16; P = 0.005). The probiotic group also showed increased total stool frequency ( P = 0.001), reduced HLS frequency ( P = 0.035), and fewer participants with CCQ scores ≥5 indicating constipation ( P < 0.001) at 4 weeks. Gut microbiota beta-diversity differed between groups after 2 weeks ( P = 0.031), with reductions in Peptococcaceae, Clostridium_methylpentosum_group, and Clostridia (unclassified at the order level), followed by increases in Lachnospiraceae_UCG-004 at 4 weeks and Lachnospiraceae_ND3007_group post-follow-up ( P < 0.050), suggesting microbial changes linked to constipation improvement. No serious adverse events related to the intervention were observed. These findings support daily LcS-fermented milk as a dietary strategy in Vietnam to manage constipation via gut microbiota modulation. The study was registered at ClinicalTrials.gov (ID: NCT05982743).

Authors

Institutions

Publication Details

Journal
Beneficial Microbes
Published
2026-04-13
DOI
https://doi.org/10.1163/18762891-bja00116
Primary Topic
Gastrointestinal motility and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effects of fermented milk containing Lacticaseibacillus paracasei strain Shirota on constipation and gut microbiota: A randomised pilot study in Vietnam

Dao Xuan Co, T. Dong Van, Hoang Van Vinh, C. Nguyen Thi Linh et al.
Beneficial Microbes
Gastrointestinal motility and disorders
article

Effects of fermented milk containing Lacticaseibacillus paracasei strain Shirota on constipation and gut microbiota: A randomised pilot study in Vietnam

Dao Xuan Co, T. Dong Van, Hoang Van Vinh, C. Nguyen Thi Linh, N. Nguyen Bao, U. Nguyen Quynh, T. Akiyama
article en

Abstract

Fermented milk containing Lacticaseibacillus paracasei strain Shirota (LcS) has been shown to improve stool consistency in various countries; however, its effect on hard or lumpy stools (HLS) in the Vietnamese population remains unclear. We investigated the effects of LcS-fermented milk on constipated Vietnamese adults with a high prevalence of HLS. In a single-centre, open-label trial, 51 participants with HLS were randomised to receive one bottle per day of fermented milk containing ≥6.5 × 109 cfu of LcS for 4 weeks (probiotic group) or no intervention (control group), followed by a 2-week washout. The primary endpoint was the proportion of participants with HLS (Bristol Stool Form Scale score of 1 or 2) in ≥25% of bowel movements over 4 weeks. Secondary endpoints included total stool frequency, HLS frequency, ideal stool form, and defecation-related symptoms - all recorded in daily diaries. The Chinese Constipation Questionnaire (CCQ) and gut microbiota composition (16S rRNA sequencing) were assessed every 2 weeks. During the intervention, the probiotic group had a significantly lower proportion of participants with HLS in ≥25% of bowel movements compared to controls (odds ratio: 0.00; 95% confidence interval: 0.00-0.16; P = 0.005). The probiotic group also showed increased total stool frequency ( P = 0.001), reduced HLS frequency ( P = 0.035), and fewer participants with CCQ scores ≥5 indicating constipation ( P < 0.001) at 4 weeks. Gut microbiota beta-diversity differed between groups after 2 weeks ( P = 0.031), with reductions in Peptococcaceae, Clostridium_methylpentosum_group, and Clostridia (unclassified at the order level), followed by increases in Lachnospiraceae_UCG-004 at 4 weeks and Lachnospiraceae_ND3007_group post-follow-up ( P < 0.050), suggesting microbial changes linked to constipation improvement. No serious adverse events related to the intervention were observed. These findings support daily LcS-fermented milk as a dietary strategy in Vietnam to manage constipation via gut microbiota modulation. The study was registered at ClinicalTrials.gov (ID: NCT05982743).

Beneficial Microbes
Hanoi National University of Education (VN), Vietnam National University, Hanoi (VN), Bạch Mai Hospital (VN), Yakult Central Institute (JP)
Openalex Percentile: Top 18%
Gastrointestinal motility and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.